pharmaphorum| News & views on pharma and biotech’s evolving future

Digital

Sponsored

12 Questions with Sam Dixey

Find out more about Sam Dixey, Head of Medical Affairs Innovation and Technology (MAIT) at LUCENT Biopharma.

News

Novartis' new SMA gene therapy cleared in EU

Novartis has secured EU approval for Itvisma, a new formulation of its spinal muscular atrophy gene therapy usable in a broader patient population.

Market Access

The GLP-1 drug revolution, head illustration visual

The GLP-1 drug revolution – and why speed alone won't save p...

R&D

The future of Oxford: Science, technology, and collaboration

In conversation with Professor Lady Sue Black and Simon Ruck about Oxford North, from opening to today.

Sales & Marketing

Changing Faces: Agency, consultancy, and investor hires, Apr...

The agency, consultancy, and investor segments saw a wave of senior-level appointments across April and May.

Featured Content

R&D

The future of Oxford: Science, technology, and collaboration

In conversation with Professor Lady Sue Black and Simon Ruck about Oxford North, from opening to today.

Market Access

The GLP-1 drug revolution – and why speed alone won't save p...

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

R&D

pharmaphorum podcast Episode 266, Parexel - Paul Bridges and Charlotte Moser

Parexel: Flawless execution, policy shifts & patient-centric...

Parexel's Paul Bridges & Charlotte Moser discuss Europe's biotech sector in the face of an innovation cliff.

Oncology

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Newsletters and Deep Dive
digital magazine

Latest News

News

Novartis' new SMA gene therapy cleared in EU

Novartis has secured EU approval for Itvisma, a new formulation of its spinal muscular atrophy gene therapy usable in a broader patient population.

News

AZ forges ever-closer ties with China's CSPC Pharma

AstraZeneca has returned to China's CSPC Pharma to fill its R&D pipeline, reaching a new $1.77bn agreement to develop drugs for kidney diseases.

News

Almost half of dementia cases could be prevented, says study

A study has found that nearly half of all cases of dementia are avoidable with lifestyle changes, but current education campaigns have limited effect.

News

Roche's KRAS drug tops its rivals in lung cancer trial

Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib.

Views & Analysis

R&D

The future of Oxford: Science, technology, and collaboration

In conversation with Professor Lady Sue Black and Simon Ruck about Oxford North, from opening to today.

Sales & Marketing

Changing Faces: Agency, consultancy, and investor hires, Apr...

The agency, consultancy, and investor segments saw a wave of senior-level appointments across April and May.

R&D

HCP and electronic clinical outcome assessments

Why are eCOA studies still so challenging?

Although eCOA has been in clinical trials for decades, we continue to hit the same road blocks during operational set-up and implementation.

Digital

Sponsored

12 Questions with Sam Dixey

Find out more about Sam Dixey, Head of Medical Affairs Innovation and Technology (MAIT) at LUCENT Biopharma.

Deep Dive

Market Access

Market Access 2026

Market Access

Five dynasties that built modern pharma

Market Access

MFN and TrumpRx: What’s the real impact for the American con...

Market Access

The expanding role of early-phase trials in modern drug deve...

White Papers & Webinar

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

Podcasts & Video

R&D

Parexel: Flawless execution, policy shifts & patient-centric...

Parexel's Paul Bridges & Charlotte Moser discuss Europe's biotech sector in the face of an innovation cliff.

Oncology

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.

Oncology

ASCO 2026: Can a blood test spot cancer early? with Dr Peter...

Dr Peter Sasieni, co-investigator for the NHS Galleri trial, discusses advances in population-level blood screening for early cancer detection.

Oncology

pharmaphorum podcast Episode 265, Leonard Mazur, Citius

6th Rare & Genetic Kidney Disease Drug Development Summit

The 6th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston on August 18–20, 2026, bringing together global leaders advanc

Featured Content

Editor's Picks

Latest News

Views & Analysis

Deep Dive

White Papers & Webinar

Podcasts & Video

Partner Content